| Toxicity |
Interacting Protein |
Mechanism |
Reference |
| Akathisia | D(2) dopamine receptor (P14416) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3) [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs
|
| Akathisia | D(3) dopamine receptor (P35462) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3) [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs
|
| Akathisia | D(4) dopamine receptor (P21917) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs
|
| Hepatotoxicity | Glutamate pyruvate transaminase (Q28DB5) | A toxic dose of the drug (LD20)produced elevated serum glutamate-pyruvate transaminase and lactate dehydrogenase activities 20-24 hr after drug administration@which leads to hepatotoxicity of acetaminophen in neonatal and young rats [ ADR Type 1 ] | Hepatotoxicity of acetaminophen in neonatal and young rats I Age-related changes in susceptibility
|
| Hepatotoxicity | L-lactate dehydrogenase (P00338) | A toxic dose of the drug (LD20)produced elevated serum glutamate-pyruvate transaminase and lactate dehydrogenase activities 20-24 hr after drug administration,which leads to hepatotoxicity of acetaminophen in neonatal and young rats. [ ADR Type 1 ] | Hepatotoxicity of acetaminophen in neonatal and young rats I Age-related changes in susceptibility
|
| Parkinsonism | NADH-ubiquinone oxidoreductase chain 1 (P03886) | Chlorpromazine produces parkinsonism apparently through inhibition of NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial electron transport chain. [ ADR Type 1 ] | Neuroleptic medications inhibit complex I of the electron transport chain
|
| Rotational Behavior | Cholinergic receptor muscarinic (Q53XZ3) | Nuclear groups adjacent to the IVth ventricle@ which are rich in muscarinic cholinergic receptors@ include locus coeruleus and vestibular nuclear complex (VNC)@their injections were significantly more likely to induce rotation [ ADR Type 1 ] | Chlorpromazine methiodide acts at the vestibular nuclear complex to induce barrel rotation in the rat
|
| Rotational Behavior | Vestibular nuclear complex (VNC) (P00063) | Nuclear groups adjacent to the IVth ventricle, which are rich in muscarinic cholinergic receptors, include locus coeruleus and vestibular nuclear complex (VNC),their injections were significantly more likely to induce rotation. [ ADR Type 1 ] | Chlorpromazine methiodide acts at the vestibular nuclear complex to induce barrel rotation in the rat
|
| Stimulated Ornithine Decarboxylase Activity | Ornithine decarboxylase (P11926) | Single dose of chlorpromazine stimulated ornithine decarboxylase activity 7-fold and decreased S-adenosylmethionine decarboxylase activity to 50% from the control level [ ADR Type 1 ] | The inverse changes of mouse brain ornithine and S-adenosylmethionine decarboxylase activities by chlorpromazine and imipramine Dependence of ornithine decarboxylase induction
|
| Stimulated Ornithine Decarboxylase Activity | S-adenosylmethionine decarboxylase (P17707) | Single dose of chlorpromazine stimulated ornithine decarboxylase activity 7-fold and decreased S-adenosylmethionine decarboxylase activity to 50% from the control level [ ADR Type 1 ] | The inverse changes of mouse brain ornithine and S-adenosylmethionine decarboxylase activities by chlorpromazine and imipramine Dependence of ornithine decarboxylase induction
|
| Tardive Dyskinesia | D(2) dopamine receptor (P14416) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3) [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs
|
| Tardive Dyskinesia | D(3) dopamine receptor (P35462) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3) [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs
|
| Tardive Dyskinesia | D(4) dopamine receptor (P21917) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs
|